Drug Trial Radar · NCT00641537
CLARITY Extension Study
Last checked: Nov 20, 2026Latest source record: Dec 7, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
867
Actual
Start
Feb 29, 2008
Primary completion
Dec 31, 2011
Study completion Dec 31, 2011
Sponsor
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 24, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this extension trial was to further evaluate the safety and tolerability of oral cladribine in subjects who have previously completed treatment within Trial 25643 (CLARITY). This trial also explored clinical benefit of prolonged 192-week versus 96-week treatment.
Conditions
- Relapsing-Remitting Multiple Sclerosis
Interventions
CladribineDrug
Participants who received Cladribine 3.5 mg/kg in the previous study 25643 (NCT00213135) and completed will be re-randomized in this extension study and receive cladribine tablet orally as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks.
PlaceboDrug
Participants who received Cladribine 3.5 mg/kg in the previous study 25643 (NCT00213135) and completed will be re-randomized in this extension study and receive placebo matched to cladribine tablet 0.875 mg/kg orally administered over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 during the treatment period of 96 weeks.
CladribineDrug
Participants who received Cladribine 5.25 mg/kg in the previous study 25643 (NCT00213135) and completed will be re-randomized in this extension study and receive cladribine tablet orally as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks.
CladribineDrug
Participants who received placebo in the previous study 25643 (NCT00213135) and completed will be re-randomized in this extension study and receive cladribine tablet orally as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks.
PlaceboDrug
Participants who received Cladribine 5.25 mg/kg in the previous study 25643 (NCT00213135) and completed will be re-randomized in this extension study and receive placebo matched to cladribine tablet 0.875 mg/kg orally administered over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 during the treatment period of 96 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety Population: Percentage of Participants With at Least 1 Common Terminology Criteria for Adverse Events Version 3.0 (CTCAE) Grade 4 Hematologic and Hepatic ToxicityTime frame: Baseline up to Week 120
- Safety Population: Mean Change From Baseline in Absolute Lymphocyte Count, Platelet, Neutrophils and Leukocytes at Week 120Time frame: Baseline, Week 120
- Safety Population: Mean Change From Baseline in Hemoglobin at Week 120Time frame: Baseline, Week 120
- Safety Population: Mean Change From Baseline in Aspartate Aminotransferase and Alanine Aminotransferase at Week 120Time frame: Baseline, Week 120
- Safety Population: Mean Change From Baseline in Bilirubin at Week 120Time frame: Baseline, Week 120
- Safety Population: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEsTime frame: Baseline up to Week 120
- SAFUP Analysis Set: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEsTime frame: Baseline up to Week 120
- Safety Population: Number of Participants Who Developed Infections (Herpes Viral Infection, Viral Infectious Disorder and Opportunistic Infection), Infection-related Adverse Events and MalignanciesTime frame: Baseline up to Week 120
- SAFUP Analysis Set: Number of Participants Who Developed Infections (Herpes Viral Infection, Viral Infectious Disorder and Opportunistic Infection), Infection-related Adverse Events and MalignanciesTime frame: Baseline up to Week 120
- Safety Population: Time to First Grade 3 or 4 Hematological Toxicity and Liver ToxicityTime frame: Baseline up to Week 120
- Safety Population: Median Time to Recovery From Grade 3 or 4 Hematological and Hepatic ToxicityTime frame: Baseline up to Week 120
- Safety Population: Mean Time to Recovery From Grade 3 or 4 Hematological and Liver ToxicityTime frame: Baseline up to Week 120
- Safety Population: Median Time to Nadir of Absolute Lymphocyte CountTime frame: Baseline up to Week 120
- Safety Population: Mean Time to Nadir of Absolute Lymphocyte CountTime frame: Baseline up to Week 120
- Safety Population: Mean Time to Recovery From Nadir of Absolute Lymphocyte Count to Normal ValueTime frame: Baseline up to Week 120
- Safety Population: Mean Change in Corrected QT (QTc) Interval From BaselineTime frame: Baseline, Week 5, 48, 52 and 96
Locations
116 sites in 31 countries. Site status is shown where the registry gives one.
Research Site
Boulder, Colorado
Research Site
Atlanta, Georgia
Research Site
Chicago, Illinois
Research Site
Northbrook, Illinois
Research Site
Baltimore, Maryland
Research Site
Ann Arbor, Michigan
Research Site
Henderson, Nevada
Research Site
Newark, New Jersey
Research Site
Charlotte, North Carolina
Research Site
Durham, North Carolina
Research Site
Columbus, Ohio
Research Site
Oklahoma City, Oklahoma
Research Site
Tulsa, Oklahoma
Research Site
Medford, Oregon
Research Site
Seattle, Washington
Research Site
Tacoma, Washington
Research Site
Charleston, West Virginia
Research Site
Camperdown, Australia
Research Site
Melbourne, Australia
Research Site
Victoria, Australia
Research Site
Linz, Austria
Research Site
Diepenbeek, Belgium
Research Site
Esneux, Belgium
Research Site
Recife, Brazil
Research Site
Pleven, Bulgaria
Research Site
Plovdiv, Bulgaria
Research Site
Rousse, Bulgaria
Research Site
Shuman, Bulgaria
Research Site
Sofia, Bulgaria
Research Site
Varna, Bulgaria
Research Site
Zagora, Bulgaria
Research Site
Burnaby, Canada
Research Site
Greenfield Park, Canada
Research Site
Ottawa, Canada
Research Site
Québec, Canada
Research Site
Karlovac, Croatia
Research Site
Sisak, Croatia
Research Site
Split, Croatia
Research Site
Hradec Králové, Czechia
Research Site
Olomouc, Czechia
Showing 40 of 116 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.